Advanced Non-small-cell Lung Cancer
Conditions
Brief summary
This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and continuing Tislelizumab in combination with docetaxel. The primary study endpoint of this study is measured by progression-free survival (PFS). 1. Tislelizumab: The recommended dose is 200 mg/dose administered every three weeks on the first day of each cycle. 2. Docetaxel: 60-75 mg/m2 every 3 weeks, administered on day 1 of each cycle. 3. Treatment cycle: Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Interventions
DRUGTislelizumab
Tislelizumab in combination with docetaxel until the development of PD, unacceptable toxicities, withdrawal of informed consent, end of study, lost to follow-up, or death, whichever occurs first.
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Advanced non-small cell lung cancer diagnosed by histology or pathology, and has progressed after first-line treatment with tislelizumab combined with platinum-containing dual-drug chemotherapy 2. Patients who have progressed after first-line tislelizumab treatment for more than 3 months 3. No EGFR, ALK gene mutations (the genetic test is not required for patients with lung squamous cell carcinoma) 4. At least one measurable lesion (RECIST standard version 1.1) 5. The expected survival period is ≥3 months 6. The ECOG-PS score is 0-2 points
Exclusion criteria
1. The tumor histology or cytology is confirmed to be mixed adenosquamous carcinoma or combined with small cell lung cancer 2. Known or suspected active autoimmune diseases 3. A history of immunodeficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and history of allogeneic bone marrow transplantation 4. Interstitial lung disease, drug-induced pneumonia, radiation pneumonia requiring steroid therapy or clinical symptoms, active pneumonia or severe lung dysfunction 5. Symptomatic brain metastases 6. Those who are known or suspected to be allergic to test drugs and their excipients 7. Women who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival | five to six months | the PFS of Tislelizumab combining with Docetaxel |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | ten to eleven months | the OS of Tislelizumab combining with Docetaxel |
Countries
China
Outcome results
None listed